Price target
24.33RUSD+13.52+125.10%
The 3 analysts offering 1 year price forecasts for Entrada Therapeutics, Inc. have a max estimate of 30.00 and a min estimate of 20.00.
Analyst rating
Based on 5 analysts giving stock ratings to Entrada Therapeutics, Inc. in the past 3 months.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong buy
5
Buy
0
Hold
0
Sell
0
Strong sell
0
EPS
Forecast
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
−1.60
−0.80
0.00
0.80
1.60
Reported
Estimate
Currency: USD
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Reported
−0.78
1.02
−0.29
0.68
1.55
−0.35
0.03
—
—
—
—
Estimate
−0.69
−0.73
−0.17
−0.59
0.36
−0.73
−0.67
−0.73
−0.76
−0.79
−0.84
Surprise
−13.07%
+238.78%
−72.19%
+214.48%
+328.94%
+51.92%
+104.48%
—
—
—
—
Revenue
Forecast
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
0.00
25.00 M
50.00 M
75.00 M
100.00 M
Reported
Estimate
Currency: USD
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Reported
18.17 M
43.73 M
41.85 M
59.12 M
94.69 M
19.57 M
37.40 M
—
—
—
—
Estimate
9.78 M
9.60 M
23.69 M
14.98 M
51.86 M
12.32 M
13.12 M
11.64 M
11.31 M
10.98 M
9.31 M
Surprise
+85.86%
+355.69%
+76.66%
+294.75%
+82.60%
+58.83%
+185.04%
—
—
—
—
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
TRDA EPS for the last quarter is 0.03 USD despite the estimation of −0.67 USD. In the next quarter EPS is expected to reach −0.73 USD. Track more of Entrada Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Entrada Therapeutics, Inc. revenue is expected to reach 11.64 M USD. Check out Entrada Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, TRDA price target is 24.33 USD with a max estimate of 30.00 USD and a min estimate of 20.00 USD. Check if this forecast comes true in a year, meanwhile watch Entrada Therapeutics, Inc. stock price chart and keep track of the current situation with TRDA news and stock market news.
We've gathered opinions of 5 analysts rating TRDA stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.